This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stocks in play: Fennec Pharmaceuticals Inc.

Baystreet.ca - Baystreet - Wed Mar 4, 9:42AM CST

Today announced that the Tampa General Hospital Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatment. Fennec Pharmaceuticals Inc. shares T.FRX are trading unchanged at $10.95.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).